Abstract:Alterations of the downstream effectors of the epidermal growth factor receptor (EGFR) are common events in colorectal cancer (CRC) carcinogenesis. Since EGFR serves as a target for therapy and some downstream effectors of EGFR have predictive and prognostic impact, reliable information on the frequency and concordance of alterations in the signaling pathway has become clinically significant. We, therefore, determined the frequency and coincidence of mutations in the EGFR pathway. We also analyzed the concordance of these alterations between primary tumor and distant metastases. Furthermore, we assessed their prognostic relevance for the development of metastasis. Mutations of KRAS exon 2, BRAF exons 11 and 15, AKT exon 3, and PIK3CA exons 9 and 20 were analyzed by pyrosequencing in 171 primary CRC samples as well as in 63 corresponding metastases. Furthermore, the expression of PTEN and EGFR was assessed by immunohistochemistry. Of the 171 tumors investigated, 60.2 % showed mutations in one or more genes of pathways downstream of EGFR. KRAS exon 2 and BRAF exon 15 mutations were detected in 40.9 and 11.1 % of cases, respectively, and were mutually exclusive. Mutations in exons 9 and 20 of the PIK3CA gene (18.7 %) largely overlapped with exon 2 KRAS mutations (16 of 32 cases; 50.0 %) and, to a lesser extent, with exon 15 mutations of BRAF (2 of 32 cases; 6.3 %). Only one case had simultaneous mutations of AKT exon 3 (0.6 %) and BRAF exon 15. Mutation analysis for KRAS exon 2, BRAF exon 15, PIK3CA exon 20, and AKT exon 3 in primary tumors and in their corresponding metastases revealed 100 % concordance. In one case, a PIK3CA exon 9 mutation in the primary tumor could not be detected in the matched distant metastases (κ = 0.9). Three different scores were applied for the evaluation of EGFR immunohistochemistry, and the range of positive cases varied between 8.8 and 52.6 %. Loss of PTEN expression was detected in 38.6 %. Although the expression of both markers does coincide with KRAS exon 2, BRAF exon 15, AKT exon 3, and PIK3CA exons 9 and 20 mutations, high discordance rates were found. The presence of at least one alteration in downstream effectors of the EGFR pathway was associated with a higher rate of distant metastases (p = 0.002). PIK3CA exons 9 and 20 mutations overlap with KRAS exon 2 and BRAF exon 15 mutations, and BRAF exon 15 and AKT exon 3 mutations co-occur in a single tumor, whereas KRAS exon 2 and BRAF exon 15 mutations are mutually exclusive. This suggests that mutations in the PIK3CA/PTEN/AKT branch of the EGFR pathway are less important than those of the RAS/RAF/MAPK branch for the progression of CRC. We found no difference in the mutational status of KRAS exon 2, BRAF exon 15, and AKT exon 3 between primary tumor and distant metastasis, validating both for diagnostic purposes. PIK3CA exons 9 and 20 mutations can be discordant between primary tumor and distant metastasis, and therefore, the lesion which is targeted for therapy should be tested. Protein expression of PTEN and EGFR using current protocols yields highly discordant results, and better standardization is needed before these markers can be used for diagnostic purposes.

Identification of MAPK and mTOR pathway alterations in HER2-amplified colorectal cancer.

Abstract 4333: High Incidence of ERBB2 Amplification Associated with Microsatellite Stable Status in Chinese Colorectal Cancer Patients

Genomic landscape of ERBB2/3 alterations in colorectal cancer: Comutations, immuno-oncology biomarkers, and consensus molecular subtype.

Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2

RAS/RAF co-mutation and ERBB2 copy number modulates HER2 heterogeneity and responsiveness to HER2-directed therapy in colorectal cancer

Abstract 7150: Molecular insights into the oncogenic influence between mutant HER3, mutant KRAS, and their synergistic interplay in colorectal cancer pathogenesis

Molecular Profiling of Patients (pts) with Advanced Colorectal Cancer (CRC): Princess Margaret Cancer Center Experience.

Effectors of epidermal growth factor receptor pathway: the genetic profiling ofKRAS, BRAF, PIK3CA, NRAS mutations in colorectal cancer characteristics and personalized medicine.

Prevalence, prognosis and predictive status of HER2 amplification in anti-EGFR-resistant metastatic colorectal cancer

Analysis Of Common Somatic Mutations In Colorectal Carcinoma And Associated Dysregulated Pathwaysarts

RAS/RAF mutations and microsatellite instability status in primary colorectal cancers according to HER2 amplification

Abstract 1923: Cytoplasmic localization of KRAS in Her2-amplified colorectal cancer induces an altered dependency of the oncogenic signaling pathway from RAS/MAPK to PI3K/AKT

Genomic profiles of BRAF inhibitor resistance mechanisms in metastatic colorectal cancer.

Oncogenic Alterations Detected by Droplet Digital PCR in Patients with Metastatic Colorectal Cancer Resistant to Cetuximab

MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway

Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer

Association of candidate alterations with primary resistance to KRAS G12D targeting in colorectal cancer.

Alterations in the EGFR pathway coincide in colorectal cancer and impact on prognosis

Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations

HER2: An emerging target in colorectal cancer

The genomic landscape of patients with advanced colorectal adenocarcinoma with PIK3CA mutations using comprehensive cell free tumor DNA next generation sequencing.